Journal
VACCINE
Volume 28, Issue 27, Pages 4376-4383Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.04.058
Keywords
Influenza; Infants; Vaccine
Categories
Funding
- sanofi pasteur
- GlaxoSmithKline
- Novartis
- MedImmune
Ask authors/readers for more resources
We assessed the effect of age on immunogenicity to trivalent inactivated influenza vaccine (TIV) by comparing the immune responses to influenza vaccine antigens among three age cohorts of vaccine-naive children aged 6-11 months, 12-17 months, and 18-23 months. In children 6-23 months of age, antibody responses to TIV appear to increase with increasing age. Despite this finding. TIV was immunogenic even in the youngest age group evaluated, further establishing its value as a tool to protect young children from influenza. The role of age should be considered when assessing improved vaccines to enhance TIV immunogenicity and effectiveness in younger children. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available